Vaxart, Inc. VXRT

VXRT Company Overview

Vaxart, Inc. is a U.S.-based biotechnology company focused on the discovery, development, and commercialization of oral recombinant protein vaccines delivered in tablet form. The company operates within the biotechnology, immunology, and vaccine development industries, with an emphasis on replacing or supplementing traditional injectable vaccines through room-temperature-stable oral immunization technologies. Its primary research and development programs have targeted infectious diseases including COVID-19, norovirus, influenza, and other viral pathogens.

The company’s core strategic differentiator is its proprietary oral vaccine platform, which is designed to stimulate both systemic and mucosal immune responses while potentially improving distribution logistics and patient compliance compared with injectable vaccines. Vaxart traces its origins to vaccine platform development work that predated its merger with Aviragen Therapeutics, Inc. in 2018, after which the combined company adopted the Vaxart name and continued advancing oral vaccine candidates through clinical development. Public filings and investor materials consistently identify clinical-stage vaccine development and platform licensing as the company’s principal business activities.